Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Up on Analyst Upgrade
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) gapped up prior to trading on Friday after Citigroup raised their price target on the stock from $338.00 to $351.00. The stock ...
Devdiscourse5h
Global Health Crisis: Measles Surges, Malnourishment Worsens, and Pharmaceuticals Rally
The document outlines various health-related news, including a measles outbreak in Texas and New Mexico, UNICEF's aid crisis ...
Stock market firms. S&P 500, Dow up for week. FedEx, Nike warn on outlooks
US stocks end up with S&P 500 and Dow gaining on the week. Focus returns to the economy and tariffs. FedEx and Nike fall ...
Alnylam price target raised to $338 from $300 at Scotiabank
Scotiabank raised the firm’s price target on Alnylam (ALNY) to $338 from $300 and keeps an Outperform rating on the shares. The firm expects Amvuttra, the first transthyretin silencer to enter the ...
Devdiscourse21h
FDA Expands Alnylam Heart Drug Approval Amid Health Policy Shifts
The FDA's approval of Alnylam's heart disease drug expands treatment options in a market poised for growth. Meanwhile, the ...
Ouster (NYSE:OUST) Sees Large Volume Increase on Analyst Upgrade
Ouster, Inc. (NYSE:OUST – Get Free Report) saw unusually-high trading volume on Friday after Cantor Fitzgerald raised their price target on the stock from $10.00 to $11.00. Cantor Fitzgerald currently ...